We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In a bid to broaden its flagship Invisalign portfolio, Align Technology, Inc. (ALGN - Free Report) recently announced the addition of Invisalign First clear aligners for treatment of younger patients with early mixed dentition. The company plans to commercially launch the new offering for Invisalign-trained doctors in the United States, Canada, Australia, New Zealand, Japan, and the EMEA region from Jul 1, 2018 onward.
We note that, more than 600 patients have been treated with the Invisalign First clear aligners to date.
Invisalign First Clear Aligners in Detail
Per the company, the latest extension of Invisalign First clear aligners have been equipped with features to aid in Phase 1 treatment of younger patients with early mixed dentition (with a mixture of primary/baby and permanent teeth). Notably, Phase 1 treatment is early interceptive orthodontic treatment for young patients typically at ages between six and 10 years.
Notably, the Invisalign First clear aligners have been developed to treat younger patients' malocclusions, including shorter clinical crowns, management of erupting dentition and predictable dental arch expansion.
Invisalign System — A Major Growth Driver
In November 2017, Align Technology announced achieving a milestone of five million patients undergoing treatment with its InvisAlign system.
Considering the fast-expanding market for clear aligner therapy, Align Technology has undertaken several strategies to drive the adoption of its core InvisAlign product line. These include product/technology development, extending clinical effectiveness, promoting the InvisAlign brand name and boosting international growth. Of late, Invisalign Technology launched an Invisalign pilot store in San Francisco that will strengthen the brand image.
Moreover, we are encouraged by Align Technology’s solid Invisalign Technology prospects and growth in North America and internationally, particularly in the Asia-Pacific region.
Market Prospects
Per a Markets and Markets report, children and teenagers will majorly comprise the global orthodontic market in the coming years. A large number of patients with malocclusions and jaw disorders are likely to drive the demand. Moreover, per Align Technology, up to 20% of orthodontic case starts each year can be attributed to Phase 1 treatment.
Research firm Technavio anticipates the global invisible orthodontics market to witness a CAGR of approximately 13% between 2016 and 2020. Given the market potential and Align Technology’s consistent efforts, we believe that the company is well positioned to cash in on the bountiful opportunities in the market.
Share Price Performance
Over the past year, Align Technology has been outperforming its broader industry. Per the latest price movement, the company’s shares have gained 116.9% compared with the 6.9% rise of the broader industry.
Zacks Rank & Other Key Picks
Align Technology carries a Zacks Rank #2 (Buy).
A few other top-ranked stocks in the broader medical sector are Bio-Rad Laboratories (BIO - Free Report) , athenahealth, Inc. and Hill-Rom Holdings, Inc. .
athenahealth is a Zacks #1 Ranked player. It has long-term expected earnings growth rate of 21.5%.
Hill-Rom has long-term expected earnings growth rate of 13.5%. The stock carries a Zacks Rank of 2.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Align Technology Broadens Invisalign Suite, Extends Reach
In a bid to broaden its flagship Invisalign portfolio, Align Technology, Inc. (ALGN - Free Report) recently announced the addition of Invisalign First clear aligners for treatment of younger patients with early mixed dentition. The company plans to commercially launch the new offering for Invisalign-trained doctors in the United States, Canada, Australia, New Zealand, Japan, and the EMEA region from Jul 1, 2018 onward.
We note that, more than 600 patients have been treated with the Invisalign First clear aligners to date.
Invisalign First Clear Aligners in Detail
Per the company, the latest extension of Invisalign First clear aligners have been equipped with features to aid in Phase 1 treatment of younger patients with early mixed dentition (with a mixture of primary/baby and permanent teeth). Notably, Phase 1 treatment is early interceptive orthodontic treatment for young patients typically at ages between six and 10 years.
Notably, the Invisalign First clear aligners have been developed to treat younger patients' malocclusions, including shorter clinical crowns, management of erupting dentition and predictable dental arch expansion.
Invisalign System — A Major Growth Driver
In November 2017, Align Technology announced achieving a milestone of five million patients undergoing treatment with its InvisAlign system.
Considering the fast-expanding market for clear aligner therapy, Align Technology has undertaken several strategies to drive the adoption of its core InvisAlign product line. These include product/technology development, extending clinical effectiveness, promoting the InvisAlign brand name and boosting international growth. Of late, Invisalign Technology launched an Invisalign pilot store in San Francisco that will strengthen the brand image.
Moreover, we are encouraged by Align Technology’s solid Invisalign Technology prospects and growth in North America and internationally, particularly in the Asia-Pacific region.
Market Prospects
Per a Markets and Markets report, children and teenagers will majorly comprise the global orthodontic market in the coming years. A large number of patients with malocclusions and jaw disorders are likely to drive the demand. Moreover, per Align Technology, up to 20% of orthodontic case starts each year can be attributed to Phase 1 treatment.
Research firm Technavio anticipates the global invisible orthodontics market to witness a CAGR of approximately 13% between 2016 and 2020. Given the market potential and Align Technology’s consistent efforts, we believe that the company is well positioned to cash in on the bountiful opportunities in the market.
Share Price Performance
Over the past year, Align Technology has been outperforming its broader industry. Per the latest price movement, the company’s shares have gained 116.9% compared with the 6.9% rise of the broader industry.
Zacks Rank & Other Key Picks
Align Technology carries a Zacks Rank #2 (Buy).
A few other top-ranked stocks in the broader medical sector are Bio-Rad Laboratories (BIO - Free Report) , athenahealth, Inc. and Hill-Rom Holdings, Inc. .
Bio-Rad Laboratories sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. It has long-term expected earnings growth rate of 20%.
athenahealth is a Zacks #1 Ranked player. It has long-term expected earnings growth rate of 21.5%.
Hill-Rom has long-term expected earnings growth rate of 13.5%. The stock carries a Zacks Rank of 2.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>